Connection

Miguel Abboud to Benzamides

Back to Details
This is a "connection" page, showing publications Miguel Abboud has written about Benzamides.
Miguel Abboud
Connection Strength
0.107
Benzamides
  1. Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon. Int J Hematol. 2012 Oct; 96(4):521-4.
    View in: PubMed
    Score: 0.095
  2. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J. 2003; 4(6):410-2.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.